
Veeva Systems (VEEV) Stock Forecast & Price Target
Veeva Systems (VEEV) Analyst Ratings
Bulls say
Veeva Systems is positioned for significant growth within the life sciences industry, with projections indicating that its "Clinical" segment will expand from approximately 21% of revenue today to about 30% by 2030, translating to a robust annual growth rate of around 21%. The company's overall top-line growth remains strong, evidenced by a 17% year-over-year revenue increase in the most recent quarter, with an implied annual growth rate of roughly 13% required to meet its $6 billion revenue goal. Additionally, Veeva's strategy of leveraging a unified platform that provides a single source of data and truth enhances operational efficiency and aligns with market demands, further bolstering its favorable financial outlook.
Bears say
Veeva Systems faces a negative outlook primarily due to potential declines in demand for its cloud-based solutions, contingent on the perceived cost savings and overall value these offerings deliver to clients. The company heavily relies on the financial health of its clients, and any continued pressure on large pharmaceutical spending and constrained funding for small biotech firms could adversely affect Veeva's revenue. Additionally, the anticipated transition of its CRM from Salesforce to Veeva Vault poses operational risks, as any significant malfunctions or delays could lead to a loss of contracts, damaging Veeva's reputation and customer base.
This aggregate rating is based on analysts' research of Veeva Systems and is not a guaranteed prediction by Public.com or investment advice.
Veeva Systems (VEEV) Analyst Forecast & Price Prediction
Start investing in Veeva Systems (VEEV)
Order type
Buy in
Order amount
Est. shares
0 shares